SBIR Phase I: Developing Next-Generation Payloads for Targeted Therapies — NSF Award to REDPOINT ONCOLOGY, INC. (MA, $305,000)
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project includes addressing critical unmet medical needs by developing an innovative platform to create new cancer therapies specifically designed to target and destroy cancer cells for a broad range of different cancers.
| Award title | SBIR Phase I: Developing Next-Generation Payloads for Targeted Therapies |
|---|---|
| Award ID | 2506212 |
| Awardee | REDPOINT ONCOLOGY, INC. |
| City | HOLDEN |
| State | MA |
| Amount obligated | $305,000 |
| Principal investigator | Mengdie Wang |
| Program | SBIR Phase I |
| Start date | 06/01/2025 |
| Abstract | The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project includes addressing critical unmet medical needs by developing an innovative platform to create new cancer therapies specifically designed to target and destroy cancer cells for a broad range of different cancers. It is estimated that approximately 90% of cancer deaths occur due to cancers becoming resistant to current treatments. This project aims to significantly enhance the effectiveness |
| Source | NSF Awards |
$799/mo
Try NSFGrants →